الإحصائيات الأساسية
| LEI | FRDRIPF3EKNDJ2CQJL29 |
| CIK | 59478 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Eli Lilly and Company
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| August 20, 2025 |
ELI LILLY AND COMPANY Officers’ Certificate Pursuant to Section 3.01 of the Indenture , 2025 EX-4.3 Exhibit 4.3 ELI LILLY AND COMPANY Officers’ Certificate Pursuant to Section 3.01 of the Indenture , 2025 The undersigned, Jon Haug, Senior Vice President, Treasurer and Corporate Finance and Investment Banking of Eli Lilly and Company, an Indiana corporation (the “Company”), and Christopher Anderson, Vice President, Leader of Corporate Securities and Assistant Secretary of the Company, purs |
|
| August 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 18, 2025 ELI LILLY AND COMPANY (Exact Name of Registrant as Specified in its Charter) Indiana 001-06351 35-0470950 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 20, 2025 |
ELI LILLY AND COMPANY Officers’ Certificate Pursuant to Section 3.01 of the Indenture , 2025 EX-4.4 Exhibit 4.4 ELI LILLY AND COMPANY Officers’ Certificate Pursuant to Section 3.01 of the Indenture , 2025 The undersigned, Jon Haug, Senior Vice President, Treasurer and Corporate Finance and Investment Banking of Eli Lilly and Company, an Indiana corporation (the “Company”), and Christopher Anderson, Vice President, Leader of Corporate Securities and Assistant Secretary of the Company, |
|
| August 20, 2025 |
ELI LILLY AND COMPANY Underwriting Agreement EX-1.1 Exhibit 1.1 ELI LILLY AND COMPANY Underwriting Agreement August 18, 2025 Citigroup Global Markets Inc. Goldman Sachs & Co. LLC J.P. Morgan Securities LLC Mizuho Securities USA LLC Morgan Stanley & Co. LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 c/o Goldman Sachs & Co. LLC 200 W |
|
| August 19, 2025 |
424B2 Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No. 333-285052 Prospectus Supplement (To Prospectus dated February 19, 2025) $6,750,000,000 Eli Lilly and Company $750,000,000 Floating Rate Notes Due 2028 Interest payable on January 15, April 15, July 15 and October 15 $1,000,000,000 4.000% Notes Due 2028 Interest payable on April 15 and October 15 $750,000,000 4.250% Notes Du |
|
| August 19, 2025 |
Calculation of Filing Fee Tables S-3 ELI LILLY & Co Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Debt Floating Rate Notes due 2028 457(r) 750,000,000 $ 750,000,000. |
|
| August 18, 2025 |
FWP Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement No. 333-285052 Dated August 18, 2025 Eli Lilly and Company $6,750,000,000 aggregate principal amount of Notes offered Pricing Term Sheet Floating Rate Notes due 2028 (the “Floating Rate Notes”) 4.000% Notes due 2028 (the “2028 Notes”) 4.250% Notes due 2031 (the “2031 Notes”) 4.550% Notes due 2032 (the “2032 Notes”) 4.900 |
|
| August 18, 2025 |
SUBJECT TO COMPLETION PRELIMINARY PROSPECTUS SUPPLEMENT, DATED AUGUST 18, 2025 424B2 Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No. 333-285052 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities is effective under the Securities Act of 1933, as amended. We are not using this preliminary prospectus supplement and the accompanying prospectus to offer to sell or |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 7, 2025 ELI LILLY AND COMPANY (Exact Name of Registrant as Specified in its Charter) Indiana 001-06351 35-0470950 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2025 COMMISSION FILE NUMBER 001-6351 ELI LILLY AND COMPANY (Exact name of Registrant as specified in its charter) Indiana 35-0470950 (State or other jurisdiction of (I.R.S. Employer incorpor |
|
| August 7, 2025 |
Lilly reports second-quarter 2025 financial results and raises guidance August 7, 2025 For release: Immediately Refer to: Ashley Hennessey; gentryashleyjo@lilly. |
|
| July 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) VERVE THERAPEUTICS, INC. (Name of Subject Company (issuer)) RIDGEWAY ACQUISITION CORPORATION (Offeror) an indirect wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Filing |
|
| July 24, 2025 |
Joint Press Release issued by Eli Lilly and Company and Verve Therapeutics, Inc. on July 24, 2025. EX-99.(a)(5)(B) Exhibit (a)(5)(B) July 24, 2025 For Release: Immediately Refer to: Ashley Hennessey; [email protected]; 317-416-4363 (Media) Michael Czapar; [email protected]; 317-617-0983 (Investors) Lilly and Verve announce expiration of Verve tender offer INDIANAPOLIS, July 24, 2025 — Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (NASDAQ: VERV) today announced tha |
|
| July 22, 2025 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) VERVE THERAPEUTICS, INC. (Name of Subject Company (issuer)) RIDGEWAY ACQUISITION CORPORATION (Offeror) an indirect wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names |
|
| July 15, 2025 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) VERVE THERAPEUTICS, INC. (Name of Subject Company (issuer)) RIDGEWAY ACQUISITION CORPORATION (Offeror) an indirect wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names |
|
| June 25, 2025 |
Offer to Purchase, dated June 25, 2025. Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of VERVE THERAPEUTICS, INC. |
|
| June 25, 2025 |
Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of VERVE THERAPEUTICS, INC. |
|
| June 25, 2025 |
Summary Advertisement, as published in The Wall Street Journal on June 25, 2025. Exhibit (a)(1)(E) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| June 25, 2025 |
Exhibit (d)(6) CONFIDENTIALITY AGREEMENT THIS CONFIDENTIALITY AGREEMENT (the “Agreement”) is made on the last date signed below, (the “Effective Date”), between Eli Lilly And Company, having its principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285, United States (“Lilly”), and Verve Therapeutics, Inc. |
|
| June 25, 2025 |
Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees. Exhibit (a)(1)(C) Offer to Purchase All Outstanding Shares of Common Stock of VERVE THERAPEUTICS, INC. |
|
| June 25, 2025 |
Form of Letter of Transmittal (including Internal Revenue Service Form W-9). Exhibit (a)(1)(B) LETTER OF TRANSMITTAL to Tender Shares of Common Stock of VERVE THERAPEUTICS, INC. |
|
| June 25, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Schedule TO VERVE THERAPEUTICS, INC. (Name of Subject Company (issuer)) RIDGEWAY ACQUISITION CORPORATION (Offeror) an indirect wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Filing Persons (identifying status as offeror, issuer or other person)) Table 1-Transaction Valuation Transaction Valuation* Fee rate Amount of F |
|
| June 25, 2025 |
Exhibit (d)(7) EXCLUSIVITY AGREEMENT This EXCLUSIVITY AGREEMENT (this “Agreement”) is effective as of May 24, 2025, by and between Verve Therapeutics, Inc. |
|
| June 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 VERVE THERAPEUTICS, INC. (Name of Subject Company (issuer)) RIDGEWAY ACQUISITION CORPORATION (Offeror) an indirect wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Filing Persons (identifyi |
|
| June 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K ý ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024. OR o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-06351 A.Full title of the plan and the addr |
|
| June 17, 2025 |
Exhibit 99.1 June 17, 2025 For Release: Immediately Refer to: Ashley Hennessey; [email protected]; 317-416-4363 (Media) Michael Czapar; [email protected]; 317-617-0983 (Investors) Ashlea Kosikowski; [email protected] (Verve) Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk Verve’s leading programs aim to deliver lifelong ca |
|
| June 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 VERVE THERAPEUTICS, INC. (Name of Subject Company (issuer)) RIDGEWAY ACQUISITION CORPORATION (Offeror) an indirect wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Filing Persons (identifyi |
|
| June 2, 2025 |
NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on June 13, 2025, pursuant to the provisions of Rule 12d2-2 (a). |
|
| May 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report ELI LILLY AND COMPANY (Exact name of registrant as specified in its charter) Indiana 001-06351 (State or other jurisdiction of incorporation) (Commission File Number) Lilly Corporate Center Indianapolis, Indiana (Address of principal executive offices) Jonathan Groff (317-450-5089) (Name a |
|
| May 9, 2025 |
Conflict Minerals Report of Eli Lilly and Company for the year ended December 31, 2024. Exhibit 1.01 Eli Lilly and Company Conflict Minerals Report For the Year Ended December 31, 2024 As required by Rule 13p-1 under the Securities Exchange Act of 1934 (the “Rule”), Eli Lilly and Company (the “Company”) has filed this Conflict Minerals Report (the “Report”). This Report covers Company products manufactured from January 1 through December 31, 2024 for which columbite-tantalite (coltan |
|
| May 8, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 5, 2025 ELI LILLY AND COMPANY (Exact Name of Registrant as Specified in its Charter) Indiana 001-06351 35-0470950 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 1, 2025 |
Lilly reports first-quarter 2025 financial results and highlights pipeline momentum May 1, 2025 For release: Immediately Refer to: Ashley Hennessey; gentryashleyjo@lilly. |
|
| May 1, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 1, 2025 ELI LILLY AND COMPANY (Exact Name of Registrant as Specified in its Charter) Indiana 001-06351 35-0470950 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2025 COMMISSION FILE NUMBER 001-6351 ELI LILLY AND COMPANY (Exact name of Registrant as specified in its charter) Indiana 35-0470950 (State or other jurisdiction of (I.R.S. Employer incorpo |
|
| March 31, 2025 |
Notice of Exempt Solicitation Pursuant to Rule 14a-103 Notice of Exempt Solicitation Pursuant to Rule 14a-103 Name of Registrant: Eli Lilly and Company (LLY) Name of person relying on exemption: John Chevedden, Eli Lilly Shareholder Address of persons relying on exemption: POB 2673, Redondo Beach, CA 90278 The attached written materials are submitted pursuant to Rule 14a-6(g)(1) promulgated under the Securities Exchange Act of 1934. |
|
| March 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| March 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| March 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| February 19, 2025 |
Trading Lilly Securities Global Procedure* Trading Lilly Securities Global Procedure Version 1.3 February 22, 2023 Exhibit 19 Trading Lilly Securities Global Procedure Basic Principles This Trading Lilly Securities Procedure (“Trading Procedure”) governs transactions in Lilly Securities and the handling of confidential information about Lilly and the companies with which Lilly does business.1 Lilly has adopted this Trading Procedure to pro |
|
| February 19, 2025 |
As filed with the U.S. Securities and Exchange Commission on February 19, 2025 Table of Contents As filed with the U.S. Securities and Exchange Commission on February 19, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Eli Lilly and Company (Exact name of registrant as specified in its charter) Indiana 35-0470950 (State or other jurisdiction of incorporati |
|
| February 19, 2025 |
Form of Relative Value Award under the 2002 Lilly Stock Plan Exhibit 10.4 Form of Relative Value Award under the 2002 Lilly Stock Plan Eli Lilly and Company Relative Value Award Agreement (for Executive Officers) This Relative Value Award has been granted on [•] (“Grant Date”) by Eli Lilly and Company, an Indiana corporation, with its principal offices in Indianapolis, Indiana (“Lilly” or the “Company”), to the Eligible Individual who has received this Rela |
|
| February 19, 2025 |
United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-K Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2024 Commission file number 001-06351 ELI LILLY AND COMPANY (Exact name of Registrant as specified in its charter) Indiana 35-0470950 (State or other jurisdiction of (I.R.S. Employer incorporati |
|
| February 19, 2025 |
Form of Restricted Stock Unit Award under the 2002 Lilly Stock Plan Exhibit 10.5 Form of Restricted Stock Unit Award under the 2002 Lilly Stock Plan Eli Lilly and Company Restricted Stock Unit Award Agreement (for Executive Officer) This Restricted Stock Unit Award has been granted on [•] (“Grant Date”) by Eli Lilly and Company, an Indiana corporation, with its principal offices in Indianapolis, Indiana (“Lilly” or the “Company”), to the Eligible Individual who ha |
|
| February 19, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Eli Lilly and Company (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registratio |
|
| February 19, 2025 |
Exhibit 21 — List of Subsidiaries & Affiliates The following are subsidiaries and affiliated companies of Eli Lilly and Company at December 31, 2024. |
|
| February 19, 2025 |
Form of Shareholder Value Award under the 2002 Lilly Stock Plan Exhibit 10.3 Form of Shareholder Value Award under the 2002 Lilly Stock Plan Eli Lilly and Company Shareholder Value Award Agreement (for Executive Officers) This Shareholder Value Award has been granted on [•] (“Grant Date”) by Eli Lilly and Company, an Indiana corporation, with its principal offices in Indianapolis, Indiana (“Lilly” or the “Company”), to the Eligible Individual who has received |
|
| February 19, 2025 |
The Lilly Directors' Deferral Plan, as amended Exhibit 10.8 The Lilly Director’s Deferral Plan, as amended ELI LILLY AND COMPANY THE LILLY DIRECTORS' DEFERRAL PLAN (as Amended and Restated Effective January 1, 2025) Preamble The Lilly Directors’ Deferral Plan has been established by the Company for the purpose of providing an opportunity for Directors of the Company who are not salaried employees of the Company to voluntarily defer receipt of |
|
| February 19, 2025 |
Exhibit 25.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) DEUTSCHE BANK TRUST COMPANY AMERICAS (formerly BANKERS TRUST COMPANY) (Exact name of trustee as specifi |
|
| February 19, 2025 |
The Lilly Deferred Compensation Plan, as amended Exhibit 10.7 The Lilly Deferred Compensation Plan, as amended ELI LILLY AND COMPANY THE LILLY DEFERRED COMPENSATION PLAN (as Amended and Restated Effective January 1, 2025) Preamble The Lilly Deferred Compensation Plan (the “Plan”) provides selected employees of Eli Lilly and Company (the “Company”) the opportunity to defer receipt of a portion of their compensation and have that deferred compensa |
|
| February 12, 2025 |
Exhibit 1.1 ELI LILLY AND COMPANY Underwriting Agreement February 10, 2025 Barclays Capital Inc. BofA Securities, Inc. Citigroup Global Markets Inc. Deutsche Bank Securities Inc. Goldman Sachs & Co. LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o Barclays Capital Inc. 745 Seventh Avenue New York, New York 10019 c/o BofA Securities, Inc. One Bryant Park New York, |
|
| February 12, 2025 |
Form of Officers’ Certificate setting forth the terms and form of the Notes. Exhibit 4.3 ELI LILLY AND COMPANY Officers’ Certificate Pursuant to Section 3.01 of the Indenture , 2025 The undersigned, Jon Haug, Senior Vice President, Treasurer and Corporate Finance and Investment Banking of Eli Lilly and Company, an Indiana corporation (the “Company”), and Christopher Anderson, Assistant Vice President, Leader of Corporate Securities and Assistant Secretary of the Company, p |
|
| February 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 10, 2025 ELI LILLY AND COMPANY (Exact Name of Registrant as Specified in its Charter) Indiana 001-06351 35-0470950 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 11, 2025 |
Filed Pursuant to Rule 424(b)(2) Registration No. 333-262943 Prospectus Supplement (To Prospectus dated February 24, 2022) $6,500,000,000 Eli Lilly and Company $1,000,000,000 4.550% Notes Due 2028 Interest payable on February 12 and August 12 $1,250,000,000 4.750% Notes Due 2030 Interest payable on February 12 and August 12 $1,000,000,000 4.900% Notes Due 2032 Interest payable on February 12 and A |
|
| February 11, 2025 |
Exhibit 107 Calculation of Filing Fee Tables (1) 424(b)(2) (Form Type) Eli Lilly and Company (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Debt 4. |
|
| February 10, 2025 |
Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement No. 333-262943 Dated February 10, 2025 Eli Lilly and Company $6,500,000,000 aggregate principal amount of Notes offered Pricing Term Sheet 4.550% Notes due 2028 (the “2028 Notes”) 4.750% Notes due 2030 (the “2030 Notes”) 4.900% Notes due 2032 (the “2032 Notes”) 5.100% Notes due 2035 (the “2035 Notes”) 5.500% Notes due 2055 ( |
|
| February 10, 2025 |
SUBJECT TO COMPLETION PRELIMINARY PROSPECTUS SUPPLEMENT, DATED FEBRUARY 10, 2025 Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No. 333-262943 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities is effective under the Securities Act of 1933, as amended. We are not using this preliminary prospectus supplement and the accompanying prospectus to offer to sell or to sol |
|
| February 6, 2025 |
Lilly reports full Q4 2024 financial results and provides 2025 guidance Feb. 6, 2025 For release: Immediately Refer to: Ashley Hennessey; [email protected]; (317) 416-4363 (Media) Mike Czapar; [email protected]; (317) 617-0983 (Investors) Lilly reports full Q4 2024 financial results and provides 2025 guidance •Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compare |
|
| February 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 6, 2025 ELI LILLY AND COMPANY (Exact Name of Registrant as Specified in its Charter) Indiana 001-06351 35-0470950 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| January 14, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 14, 2025 ELI LILLY AND COMPANY (Exact Name of Registrant as Specified in its Charter) Indiana 001-06351 35-0470950 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| January 14, 2025 |
January 14, 2025 For Release: Immediately Refer to: Carrie Munk; munkcarrie@lilly. |
|
| November 19, 2024 |
Lilly announces changes on board of directors November 19, 2024 For Release: Immediately Refer to: Carrie Munk; munkcarrie@lilly. |
|
| November 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 19, 2024 ELI LILLY AND COMPANY (Exact Name of Registrant as Specified in its Charter) Indiana 001-06351 35-0470950 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 14, 2024 |
LLY / Eli Lilly and Company / PNC FINANCIAL SERVICES GROUP, INC. - SC 13G/A Passive Investment SC 13G/A 1 d884825dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 5) Eli Lilly and Company (Name of Issuer) Common Stock (Title of Class of Securities) 532457108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2024 COMMISSION FILE NUMBER 001-6351 ELI LILLY AND COMPANY (Exact name of Registrant as specified in its charter) Indiana 35-0470950 (State or other jurisdiction of (I.R.S. Employer inc |
|
| October 30, 2024 |
Oct. 30, 2024 For release: Immediately Refer to: Jordan Bishop; [email protected]; (317) 374-1878 (Media) Joe Fletcher; [email protected]; (317) 296-2884 (Investors) Lilly reports Q3 2024 financial results highlighted by strong volume-driven revenue growth from New Products •Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 bill |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 30, 2024 ELI LILLY AND COMPANY (Exact Name of Registrant as Specified in its Charter) Indiana 001-06351 35-0470950 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| October 23, 2024 |
SC 13G/A 1 lilly241106sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 40) Eli Lilly and Company (Name of Issuer) Common Stock, Without Par Value (Title of Class of Securities) 532457-10-8 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check th |
|
| September 9, 2024 |
Sept. 9, 2024 For Release: Immediately Refer to: Jordan Bishop; [email protected]; (317) 473-5712 (Media) Joe Fletcher; [email protected]; (317) 296-2884 (Investors) Lilly appoints Lucas Montarce as executive vice president and chief financial officer INDIANAPOLIS, Sept. 9, 2024 – Eli Lilly and Company (NYSE: LLY) today announced the appointment of Lucas Montarce as executive vice presiden |
|
| September 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 5, 2024 ELI LILLY AND COMPANY (Exact Name of Registrant as Specified in its Charter) Indiana 001-06351 35-0470950 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 13, 2024 ELI LILLY AND COMPANY (Exact Name of Registrant as Specified in its Charter) Indiana 001-06351 35-0470950 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 16, 2024 |
Lilly announces retirement of Marschall S. Runge from its Board of Directors Aug. 16, 2024 For Release: Immediately Refer to: Jordan Bishop; [email protected]; 317-374-1878 (Media) Joe Fletcher; [email protected]; 317-296-2884 (Investors) Lilly announces retirement of Marschall S. Runge from its Board of Directors INDIANAPOLIS, Aug. 16, 2024 - Eli Lilly and Company (NYSE: LLY) announced today that Marschall S. Runge, M.D., Ph.D. is retiring from his role as an inde |
|
| August 16, 2024 |
Press Release issued by Lilly on August 16, 2024. EX-99.(a)(5)(B) Exhibit (a)(5)(B) Aug. 16, 2024 For Release: Immediately Refer to: Jordan Bishop; [email protected]; 317-374-1878 (Media) Joe Fletcher; [email protected]; 317-296-2884 (Investors) Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease Broadens Lilly’s immunology pipeline with Morphic’s oral integrin th |
|
| August 16, 2024 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) MORPHIC HOLDING, INC. (Name of Subject Company (issuer)) RAINIER ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Filing Pers |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 12, 2024 ELI LILLY AND COMPANY (Exact Name of Registrant as Specified in its Charter) Indiana 001-06351 35-0470950 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 14, 2024 |
Exhibit 1.1 Execution Version ELI LILLY AND COMPANY Underwriting Agreement August 12, 2024 BNP Paribas Securities Corp. Citigroup Global Markets Inc. Goldman Sachs & Co. LLC J.P. Morgan Securities LLC Morgan Stanley & Co. LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o BNP Paribas Securities Corp. 787 Seventh Avenue New York, New York 10019 c/o Citigroup Global M |
|
| August 14, 2024 |
Form of Officers’ Certificate setting forth the terms and form of the Notes. Exhibit 4.3 ELI LILLY AND COMPANY Officers’ Certificate Pursuant to Section 3.01 of the Indenture , 2024 The undersigned, Gordon Brooks, Interim Chief Financial Officer, Group Vice President, Controller and Corporate Strategy of Eli Lilly and Company, an Indiana corporation (the “Company”), and Christopher Anderson, Assistant Vice President, Leader of Corporate Securities and Assistant Secretary o |
|
| August 13, 2024 |
Exhibit 107 Calculation of Filing Fee Tables (1) 424(b)(2) (Form Type) Eli Lilly and Company (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Debt 4. |
|
| August 13, 2024 |
424B2 Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No. 333-262943 Prospectus Supplement (To Prospectus dated February 24, 2022) $5,000,000,000 Eli Lilly and Company $750,000,000 4.150% Notes Due 2027 Interest payable on February 14 and August 14 $1,000,000,000 4.200% Notes Due 2029 Interest payable on February 14 and August 14 $1,250,000,000 4.600% Notes Due 2034 Interest payabl |
|
| August 12, 2024 |
Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement No. 333-262943 Dated August 12, 2024 Eli Lilly and Company $5,000,000,000 aggregate principal amount of Notes offered Pricing Term Sheet 4.150% Notes due 2027 (the “2027 Notes”) 4.200% Notes due 2029 (the “2029 Notes”) 4.600% Notes due 2034 (the “2034 Notes”) 5.050% Notes due 2054 (the “2054 Notes”) 5.200% Notes due 2064 (th |
|
| August 12, 2024 |
SUBJECT TO COMPLETION PRELIMINARY PROSPECTUS SUPPLEMENT, DATED AUGUST 12, 2024 424B2 Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No. 333-262943 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities is effective under the Securities Act of 1933, as amended. We are not using this preliminary prospectus supplement and the accompanying prospectus to offer to sell or |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2024 COMMISSION FILE NUMBER 001-6351 ELI LILLY AND COMPANY (Exact name of Registrant as specified in its charter) Indiana 35-0470950 (State or other jurisdiction of (I.R.S. Employer incorpor |
|
| August 8, 2024 |
Amended and Restated 2002 Lilly Stock Plan* Exhibit 10.1 Amended and Restated 2002 Lilly Stock Plan AMENDED AND RESTATED 2002 LILLY STOCK PLAN (As amended, May 6, 2024) ARTICLE 1. PURPOSES OF THE PLAN The Company believes that this Amended and Restated 2002 Lilly Stock Plan, as amended from time to time (the “Plan”), will benefit the Company’s shareholders by allowing the Company to attract, motivate and retain the best available Employees |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 8, 2024 ELI LILLY AND COMPANY (Exact Name of Registrant as Specified in its Charter) Indiana 001-06351 35-0470950 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 8, 2024 |
Lilly Reports Q2 2024 Financial Results, Raises Full-Year Revenue Guidance by $3 Billion Aug. 8, 2024 For Release: Immediately Refer to: Jordan Bishop; [email protected]; (317) 374-1878 (Media) Joe Fletcher; [email protected]; (317) 296-2884 (Investors) Lilly Reports Q2 2024 Financial Results, Raises Full-Year Revenue Guidance by $3 Billion •Revenue in Q2 2024 increased 36%, driven by Mounjaro, Zepbound and Verzenio. When excluding $579.0 million of revenue from the sale of ri |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) MORPHIC HOLDING, INC. (Name of Subject Company (issuer)) RAINIER ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Filing Persons (ident |
|
| August 1, 2024 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) MORPHIC HOLDING, INC. (Name of Subject Company (issuer)) RAINIER ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Filing Pers |
|
| July 19, 2024 |
Exhibit (d)(5) MUTUAL AGREEMENT OF CONFIDENTIALITY This Mutual Agreement of Confidentiality (this “Agreement”) dated as of the last date signed below (the “Effective Date”) is made by and between Morphic Therapeutic, Inc. |
|
| July 19, 2024 |
Exhibit (d)(8) THIRD AMENDMENT TO MUTUAL CONFIDENTIALITY AGREEMENT Eli Lilly and Company and Morphic Therapeutic, Inc. |
|
| July 19, 2024 |
Exclusivity Agreement, dated June 25, 2024, between Eli Lilly and Company and Morphic Holding, Inc. Exhibit (d)(10) EXCLUSIVITY AGREEMENT This EXCLUSIVITY AGREEMENT (this “Agreement”) is effective as of June 25, 2024, by and between Morphic Holding, Inc. |
|
| July 19, 2024 |
Summary Advertisement, as published in The Wall Street Journal on July 19, 2024. Exhibit (a)(1)(E) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| July 19, 2024 |
Exhibit (d)(6) FIRST AMENDMENT TO CONFIDENTIALITY AGREEMENT Eli Lilly and Company and Morphic Therapeutic, Inc. |
|
| July 19, 2024 |
Exhibit (d)(7) SECOND AMENDMENT TO MUTUAL CONFIDENTIALITY AGREEMENT Eli Lilly and Company and Morphic Therapeutic, Inc. |
|
| July 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 MORPHIC HOLDING, INC. (Name of Subject Company (issuer)) RAINIER ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Filing Persons (identifying status as o |
|
| July 19, 2024 |
Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of MORPHIC HOLDING, INC. |
|
| July 19, 2024 |
Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees. Exhibit (a)(1)(C) Offer to Purchase All Outstanding Shares of Common Stock of MORPHIC HOLDING, INC. |
|
| July 19, 2024 |
Offer to Purchase, dated July 19, 2024. Table of Contents Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of MORPHIC HOLDING, INC. |
|
| July 19, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Schedule TO MORPHIC HOLDING, INC. (Name of Subject Company (issuer)) RAINIER ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Filing Persons (identifying status as offeror, issuer or other person)) Table 1-Transaction Valuation Transaction Valuation* Fee rate Amount of Filing Fee** F |
|
| July 19, 2024 |
Exhibit (d)(9) FOURTH AMENDMENT TO MUTUAL CONFIDENTIALITY AGREEMENT Eli Lilly and Company and Morphic Therapeutic, Inc. |
|
| July 19, 2024 |
Form of Letter of Transmittal (including Internal Revenue Service Form W-9). Exhibit (a)(1)(B) LETTER OF TRANSMITTAL to Tender Shares of Common Stock of MORPHIC HOLDING, INC. |
|
| July 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 5, 2024 ELI LILLY AND COMPANY (Exact Name of Registrant as Specified in its Charter) Indiana 001-06351 35-0470950 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| July 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 MORPHIC HOLDING, INC. (Name of Subject Company (issuer)) RAINIER ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Filing Persons (identifying status as o |
|
| July 8, 2024 |
Exhibit 99.1 July 8, 2024 For Release: Immediately Refer to: Jordan Bishop; [email protected]; 317-473-5712 (Lilly Media) Joe Fletcher; [email protected]; 317-296-2884 (Lilly Investors) Chris Erdman; [email protected]; 617-686-1718 (Morphic) Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease Acquisition to expand Lilly’s immunology pipeline w |
|
| June 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K ý ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023. OR o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-06351 A.Full title of the plan and the addr |
|
| June 5, 2024 |
Lilly announces departure of Anat Ashkenazi, chief financial officer June 5, 2024 For Release: Immediately Refer to: Tarsis Lopez; [email protected]; (224) 406-2746 (Media) Joe Fletcher; [email protected]; (317) 296-2884 (Investors) Lilly announces departure of Anat Ashkenazi, chief financial officer INDIANAPOLIS, June 5, 2024 – Eli Lilly and Company (NYSE: LLY) announced today that Anat Ashkenazi has resigned as chief financial officer to pursue a career op |
|
| June 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 2, 2024 ELI LILLY AND COMPANY (Exact Name of Registrant as Specified in its Charter) Indiana 001-06351 35-0470950 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 9, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 6, 2024 ELI LILLY AND COMPANY (Exact Name of Registrant as Specified in its Charter) Indiana 001-06351 35-0470950 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report ELI LILLY AND COMPANY (Exact name of registrant as specified in its charter) Indiana 001-06351 (State or other jurisdiction of incorporation) (Commission File Number) Lilly Corporate Center Indianapolis, Indiana (Address of principal executive offices) Jonathan Groff (317-450-5089) (Name a |
|
| May 3, 2024 |
Conflict Minerals Report of Eli Lilly and Company for the year ended December 31, 2023. Exhibit 1.01 Eli Lilly and Company Conflict Minerals Report For the Year Ended December 31, 2023 As required by Rule 13p-1 under the Securities Exchange Act of 1934 (the “Rule”), Eli Lilly and Company (the “Company”) has filed this Conflict Minerals Report (the “Report”). This Report covers Company products manufactured from January 1 through December 31, 2023 for which columbite-tantalite (coltan |
|
| April 30, 2024 |
April 30, 2024 For Release: Immediately Refer to: Jordan Bishop; [email protected]; (317) 473-5712 (Media) Joe Fletcher; [email protected]; (317) 296-2884 (Investors) Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum •Revenue in Q1 2024 increased 26%, driven by Mounjaro, Zepbound, Verzenio and Jardiance. •Pi |
|
| April 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 COMMISSION FILE NUMBER 001-6351 ELI LILLY AND COMPANY (Exact name of Registrant as specified in its charter) Indiana 35-0470950 (State or other jurisdiction of (I.R.S. Employer incorpo |
|
| April 30, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 30, 2024 ELI LILLY AND COMPANY (Exact Name of Registrant as Specified in its Charter) Indiana 001-06351 35-0470950 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| April 11, 2024 |
Main Post Office, P.O. Box 751 www.asyousow.org Berkeley, CA 94704 BUILDING A SAFE, JUST, AND SUSTAINABLE WORLD SINCE 1992 Notice of Exempt Solicitation Pursuant to Rule 14a-103 Name of the Registrant: Eli Lilly and Co. (LLY) Name of persons relying on exemption: As You Sow™ Address of persons relying on exemption: Main Post Office, P.O. Box 751, Berkeley, CA 94704 Written materials are submitted |
|
| April 4, 2024 |
Eli Lilly and Company Vote FOR: Item #9 Annual Meeting: May 6, 2024 Notice of Exempt Solicitation NAME OF REGISTRANT: Eli Lilly and Company NAME OF PERSON RELYING ON EXEMPTION: CommonSpirit Health ADDRESS OF PERSON RELYING ON EXEMPTION: 2039 N. |
|
| March 28, 2024 |
VOTE FOR ITEM 6 AT ELI LILLY’S ANNUAL MEETING ON MAY 6, 2024 Notice of Exempt Solicitation Name of Registrant: Eli Lilly and Company Name of Person Relying on Exemption: SEIU Benefit Plans Master Trust Address of Person Relying on Exemption: 1800 Massachusetts Avenue, NW, Washington, DC 20036 Written materials are submitted pursuant to Rule 14a-6(g)(1) promulgated under the Securities Exchange Act of 1934. |
|
| March 28, 2024 |
Eli Lilly and Company (LLY) Shareholder Alert Voluntary submission by John Chevedden, POB 2673, Redondo Beach, CA 90278 LLY Shareholder since 2018 Important to Vote for the Board of Directors Simple Majority Vote Proposal 5 Proposal 5 will help improve LLY shareholder rights. |
|
| March 28, 2024 |
NOTICE OF EXEMPT SOLICITATION NAME OF REGISTRANT: Eli Lilly and Company NAME OF PERSON RELYING ON EXEMPTION: Trinity Health ADDRESS OF PERSON RELYING ON EXEMPTION: Catherine Rowan Dear Fellow Eli Lilly Shareholder, Trinity Health and co-filers Adrian Dominican Sisters, Friends Fiduciary Corporation, Mercy Investment Services, Sisters of Charity of St. |
|
| March 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| March 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| March 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| February 21, 2024 |
Exhibit 21 — List of Subsidiaries & Affiliates The following are subsidiaries and affiliated companies of Eli Lilly and Company at December 31, 2023. |
|
| February 21, 2024 |
2007 Change in Control Severance Pay Plan for Select Employees, as amended Exhibit 10.10 2007 Change in Control Severance Plan for Select Employees, as amended ELI LILLY AND COMPANY 2007 CHANGE IN CONTROL SEVERANCE PAY PLAN FOR SELECT EMPLOYEES As Amended Effective January 1, 2024 1. PURPOSE This Eli Lilly and Company 2007 Change in Control Severance Pay Plan For Select Employees has been established by the Company to provide for the payment of severance pay and benefits |
|
| February 21, 2024 |
Form of Relative Value Award under the 2002 Lilly Stock Plan Exhibit 10.4 Form of Relative Value Award under the 2002 Lilly Stock Plan Eli Lilly and Company Relative Value Award Agreement (for Executive Officers) This Relative Value Award has been granted on [•] (“Grant Date”) by Eli Lilly and Company, an Indiana corporation, with its principal offices in Indianapolis, Indiana (“Lilly” or the “Company”), to the Eligible Individual who has received this Rela |
|
| February 21, 2024 |
Form of Shareholder Value Award under the 2002 Lilly Stock Plan Exhibit 10.3 Form of Shareholder Value Award under the 2002 Lilly Stock Plan Eli Lilly and Company Shareholder Value Award Agreement (for Executive Officers) This Shareholder Value Award has been granted on [•] (“Grant Date”) by Eli Lilly and Company, an Indiana corporation, with its principal offices in Indianapolis, Indiana (“Lilly” or the “Company”), to the Eligible Individual who has received |
|
| February 21, 2024 |
United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-K Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023 Commission file number 001-06351 ELI LILLY AND COMPANY (Exact name of Registrant as specified in its charter) Indiana 35-0470950 (State or other jurisdiction of (I.R.S. Employer incorporati |
|
| February 21, 2024 |
Executive Compensation Recovery Policy* Exhibit 97 Executive Compensation Recovery Policy Executive Compensation Recovery Policy Effective October 2, 2023 (the “Effective Date”) Purpose and Scope Eli Lilly and Company (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. |
|
| February 21, 2024 |
Form of Restricted Stock Unit Award under the 2002 Lilly Stock Plan Exhibit 10.5 Form of Restricted Stock Unit Award under the 2002 Lilly Stock Plan Eli Lilly and Company Restricted Stock Unit Award Agreement (for Executive Officer) This Restricted Stock Unit Award has been granted on [•] (“Grant Date”) by Eli Lilly and Company, an Indiana corporation, with its principal offices in Indianapolis, Indiana (“Lilly” or the “Company”), to the Eligible Individual who ha |
|
| February 21, 2024 |
Description of the Company's Common Stock* Exhibit 4.3 Description of Common Stock The following summary of Eli Lilly and Company’s common stock is based on and qualified by, among other things, our amended articles of incorporation and our bylaws, both of which are filed as exhibits to our Annual Report on Form 10-K. Throughout this exhibit, references to “we,” “Company,” “our,” and “us” refer to Eli Lilly and Company. As of the filing da |
|
| February 13, 2024 |
LLY / Eli Lilly and Company / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0827-elilillyco.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Eli Lilly & Co Title of Class of Securities: Common Stock CUSIP Number: 532457108 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule |
|
| February 9, 2024 |
EX-1.1 Exhibit 1.1 Execution Version ELI LILLY AND COMPANY Underwriting Agreement February 7, 2024 BofA Securities, Inc. Barclays Capital Inc. Citigroup Global Markets Inc. Deutsche Bank Securities Inc. Mizuho Securities USA LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o BofA Securities, Inc. One Bryant Park New York, New York 10036 c/o Barclays Capital Inc. 745 |
|
| February 9, 2024 |
LLY / Eli Lilly and Company / PNC FINANCIAL SERVICES GROUP, INC. - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 4) Eli Lilly and Company (Name of Issuer) Common Stock (Title of Class of Securities) 532457108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sched |
|
| February 9, 2024 |
EX-99.A Page 9 of 9 Pages EXHIBIT A AGREEMENT February 9, 2024 The undersigned hereby agree to file a joint statement on Schedule 13G under the Securities and Exchange Act of 1934, as amended (the “Act”) with respect to the shares of common stock issued by Eli Lilly and Company. Each of the undersigned states that it is entitled to individually use Schedule 13G pursuant to Rule 13d-1(b) of the Act |
|
| February 9, 2024 |
Form of Officers’ Certificate setting forth the terms and form of the Notes. EX-4.3 Exhibit 4.3 ELI LILLY AND COMPANY Officers’ Certificate Pursuant to Section 3.01 of the Indenture , 2024 The undersigned, Philip Johnson, Group Vice President, Finance and Treasurer of Eli Lilly and Company, an Indiana corporation (the “Company”), and Jonathan Groff, Executive Director – Corporate Securities and Assistant Secretary of the Company, pursuant to Section 3.01 of the Indentu |
|
| February 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 7, 2024 ELI LILLY AND COMPANY (Exact Name of Registrant as Specified in its Charter) Indiana 001-06351 35-0470950 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| February 8, 2024 |
Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No. 333-262943 Prospectus Supplement (To Prospectus dated February 24, 2022) $6,500,000,000 Eli Lilly and Company $1,000,000,000 4.500% Notes Due 2027 Interest payable on February 9 and August 9 $1,000,000,000 4.500% Notes Due 2029 Interest payable on February 9 and August 9 $1,500,000,000 4.700% Notes Due 2034 Interest payable on Feb |
|
| February 8, 2024 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables(1) 424(b)(2) (Form Type) Eli Lilly and Company (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Debt 4. |
|
| February 7, 2024 |
SUBJECT TO COMPLETION PRELIMINARY PROSPECTUS SUPPLEMENT, DATED FEBRUARY 7, 2024 Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No. 333-262943 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities is effective under the Securities Act of 1933, as amended. We are not using this preliminary prospectus supplement and the accompanying prospectus to offer to sell or to sol |
|
| February 7, 2024 |
Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement No. 333-262943 Dated February 7, 2024 Eli Lilly and Company $6,500,000,000 aggregate principal amount of Notes offered Pricing Term Sheet 4.500% Notes due 2027 (the “2027 Notes”) 4.500% Notes due 2029 (the “2029 Notes”) 4.700% Notes due 2034 (the “2034 Notes”) 5.000% Notes due 2054 (the “2054 Notes”) 5.100% Notes due 2064 (t |
|
| February 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 6, 2024 ELI LILLY AND COMPANY (Exact Name of Registrant as Specified in its Charter) Indiana 001-06351 35-0470950 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| February 6, 2024 |
Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance Feb. 6, 2024 For Release: Immediately Refer to: Jordan Bishop; [email protected]; (317) 473-5712 (Media) Joe Fletcher; [email protected]; (317) 296-2884 (Investors) Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance •Revenue in Q4 2023 increased 28%. New Products(i) revenue grew by $2.19 billion to $2.49 billion in Q4 2023, led by Mounjaro and Zepbound. G |
|
| January 26, 2024 |
LLY / Eli Lilly and Company / LILLY ENDOWMENT INC - SC 13G/A Passive Investment SC 13G/A 1 lilly240086sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 39) Eli Lilly and Company (Name of Issuer) Common Stock, Without Par Value (Title of Class of Securities) 532457-10-8 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the |
|
| December 26, 2023 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 7) POINT BIOPHARMA GLOBAL INC. (Name of Subject Company (issuer)) YOSEMITE FALLS ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names o |
|
| December 18, 2023 |
Press Release issued by Lilly on December 18, 2023. EX-99.(a)(5)(F) Exhibit (a)(5)(F) Dec. 18, 2023 For Release: Dec. 18, 2023 @ 6:45 a.m. ET Refer to: Jordan Bishop; [email protected]; 317-473-5712 (Media) Joe Fletcher; [email protected]; 317-296-2884 (Investors) Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 22, 2023 INDIANAPOLIS, Dec. 18, 2023 – Eli Lilly and Company (NYSE: LLY) today announced the extension of the expirat |
|
| December 18, 2023 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 6) POINT BIOPHARMA GLOBAL INC. (Name of Subject Company (issuer)) YOSEMITE FALLS ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names o |
|
| December 4, 2023 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(a) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 5) POINT BIOPHARMA GLOBAL INC. (Name of Subject Company (issuer)) YOSEMITE FALLS ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names o |
|
| December 4, 2023 |
Press Release issued by Lilly on December 4, 2023. Exhibit (a)(5)(E) Dec. 4, 2023 For Release: Dec. 4, 2023 @ 6:45 a.m. ET Refer to: Jordan Bishop; [email protected]; 317-473-5712 (Media) Joe Fletcher; [email protected]; 317-296-2884 (Investors) Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023 INDIANAPOLIS, Dec. 4, 2023 – Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender o |
|
| November 17, 2023 |
Press Release issued by Lilly on November 17, 2023. EX-99.(A)(5)(D) Exhibit (a)(5)(D) Nov. 17, 2023 For Release: Nov. 17, 2023 @ 6:45 a.m. ET Refer to: Jordan Bishop; [email protected]; 317-473-5712 (Media) Joe Fletcher; [email protected]; 317-296-2884 (Investors) Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023 INDIANAPOLIS, Nov. 17, 2023 – Eli Lilly and Company (NYSE: LLY) today announced the extension of the expirati |
|
| November 17, 2023 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(a) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 4) POINT BIOPHARMA GLOBAL INC. (Name of Subject Company (issuer)) YOSEMITE FALLS ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names o |
|
| November 15, 2023 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. SCHEDULE TO Tender Offer Statement under Section 14(d)(a) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) POINT BIOPHARMA GLOBAL, INC. (Name of Subject Company (issuer)) YOSEMITE FALLS ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Fil |
|
| November 15, 2023 |
Press Release issued by Lilly on November 14, 2023. EX-99.(A)(5)(C) Exhibit (a)(5)(C) Nov. 14, 2023 For Release: Immediately Refer to: Jordan Bishop; [email protected]; 317-473-5712 (Media) Joe Fletcher; [email protected]; 317-296-2884 (Investors) Lilly Announces the Receipt of NRC Consent in Connection with its Proposed Acquisition of POINT Biopharma INDIANAPOLIS, Nov. 14, 2023 – Eli Lilly and Company (NYSE: LLY) today announced that the U |
|
| November 9, 2023 |
November 9, 2023 By EDGAR submission Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission 100 F Street N. |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(a) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) POINT BIOPHARMA GLOBAL INC. (Name of Subject Company (issuer)) YOSEMITE FALLS ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Filing P |
|
| November 8, 2023 |
Press Release issued by Lilly on November 8, 2023. Exhibit (a)(5)(B) For Release: Nov.8, 2023 @ 4:45 p.m. ET Refer to: Jordan Bishop; [email protected]; 317-473-5712 (Media) Joe Fletcher; [email protected]; 317-296-2884 (Investors) Lilly Announces Extension of Tender Offer to Acquire POINT Biopharma INDIANAPOLIS, Nov. 8, 2023 – Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire |
|
| November 2, 2023 |
Nov. 2, 2023 For Release: Immediately Refer to: Jordan Bishop; [email protected]; (317) 473-5712 (Media) Joe Fletcher; [email protected]; (317) 296-2884 (Investors) Lilly Reports Third-Quarter 2023 Financial Results, Highlights Strong Sales Growth and Business Development Activity •Revenue in Q3 2023 increased 37%, driven by growth from Mounjaro, Verzenio and Jardiance, as well as $1.42 bi |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 2, 2023 ELI LILLY AND COMPANY (Exact Name of Registrant as Specified in its Charter) Indiana 001-06351 35-0470950 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2023 COMMISSION FILE NUMBER 001-6351 ELI LILLY AND COMPANY (Exact name of Registrant as specified in its charter) Indiana 35-0470950 (State or other jurisdiction of (I.R.S. Employer inc |
|
| October 27, 2023 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) POINT BIOPHARMA GLOBAL INC. (Name of Subject Company (issuer)) YOSEMITE FALLS ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names o |
|
| October 26, 2023 |
October 26, 2023 By EDGAR submission Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission 100 F Street N. |
|
| October 13, 2023 |
SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 POINT BIOPHARMA GLOBAL INC. (Name of Subject Company (issuer)) YOSEMITE FALLS ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Filing Persons (id |
|
| October 13, 2023 |
Offer to Purchase, dated October 13, 2023. EX-99.(a)(1)(A) Table of Contents Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of POINT BIOPHARMA GLOBAL INC. at $12.50 per share, net in cash, without interest and less any applicable tax withholding by YOSEMITE FALLS ACQUISITION CORPORATION a wholly-owned subsidiary of ELI LILLY AND COMPANY THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE PAST 11:59 P.M., E |
|
| October 13, 2023 |
EX-99.(a)(1)(D) Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of POINT BIOPHARMA GLOBAL INC. at $12.50 per share, net in cash, without interest and less any applicable tax withholding Pursuant to the Offer to Purchase dated October 13, 2023 by YOSEMITE FALLS ACQUISITION CORPORATION a wholly-owned subsidiary of ELI LILLY AND COMPANY THE OFFER AND WITHDRAWAL RIGHTS WILL |
|
| October 13, 2023 |
EX-99.(d)(5) Exhibit (d)(5) CONFIDENTIALITY AGREEMENT THIS CONFIDENTIALITY AGREEMENT (the “Agreement”) is made on the last date signed below, (the “Effective Date”), between Eli Lilly and Company and its Affiliates, having its principal place of business at Lilly Corporate Center, Indianapolis, IN 46285, United States (“Lilly”), and Point Biopharma Global, Inc., having its principal place of busin |
|
| October 13, 2023 |
Summary Advertisement, as published in The Wall Street Journal on October 13, 2023. EX-99.(a)(1)(E) Exhibit (a)(1)(E) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). The Offer (as defined below) is being made only by the Offer to Purchase, dated October 13, 2023 (the “Offer to Purchase”) and the related Letter of Transmittal, as each may be amended or supplemented from time to time, and is being made to all holde |
|
| October 13, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Schedule TO POINT BIOPHARMA GLOBAL INC. |
|
| October 13, 2023 |
Form of Letter of Transmittal (including Internal Revenue Service Form W-9). EX-99.(a)(1)(B) Exhibit (a)(1)(B) LETTER OF TRANSMITTAL to Tender Shares of Common Stock of POINT BIOPHARMA GLOBAL INC. at $12.50 per share, net in cash, without interest and less any applicable tax withholding Pursuant to the Offer to Purchase dated October 13, 2023 by YOSEMITE FALLS ACQUISITION CORPORATION a wholly-owned subsidiary of ELI LILLY AND COMPANY THE OFFER AND WITHDRAWAL RIGHTS WILL EX |
|
| October 13, 2023 |
Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees. EX-99.(a)(1)(C) Exhibit (a)(1)(C) Offer to Purchase All Outstanding Shares of Common Stock of POINT BIOPHARMA GLOBAL INC. at $12.50 per share, net in cash, without interest and less any applicable tax withholding Pursuant to the Offer to Purchase dated October 13, 2023 by YOSEMITE FALLS ACQUISITION CORPORATION a wholly-owned subsidiary of ELI LILLY AND COMPANY THE OFFER AND WITHDRAWAL RIGHTS WILL |
|
| October 5, 2023 |
October 5, 2023 By EDGAR submission Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission 100 F Street N. |
|
| October 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 POINT BIOPHARMA GLOBAL INC. (Name of Subject Company (issuer)) YOSEMITE FALLS ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Filing Persons (identifyin |
|
| October 3, 2023 |
EX-99.1 Exhibit 99.1 For Release: Oct. 3, 2023 @ 6:45 a.m. ET Refer to: Jordan Bishop; [email protected]; 317-473-5712 (Media) Joe Fletcher; [email protected]; 317-296-2884 (Investors) Daniel Pearlstein; [email protected] (POINT Investors) Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies INDIANAPOLIS, Oct. 3, 2023 – |
|
| September 20, 2023 |
September 20, 2023 By EDGAR submission Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission 100 F Street N. |
|
| August 14, 2023 |
Lilly Completes Acquisition of Sigilon Therapeutics EX-2.3 Exhibit 2.3 Aug. 14, 2023 For Release: Immediately Refer to: Jordan Bishop; [email protected]; 317-473-5712 (Media) Joe Fletcher; [email protected]; 317-296-2884 (Investors) Lilly Completes Acquisition of Sigilon Therapeutics INDIANAPOLIS, Aug. 14, 2023 — Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Sigilon Therapeutics, Inc. (NAS |
|
| August 14, 2023 |
US82657L2060 / SIGILON THERAPEUTICS INC / ELI LILLY & Co - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 1)* Under the Securities Exchange Act of 1934 Sigilon Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 82657L206 (CUSIP Number) Anat Hakim Executive Vice President, General Counsel and Secretary Eli Lilly and Company Lilly Corporate |
|
| August 10, 2023 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) SIGILON THERAPEUTICS, INC. (Name of Subject Company (issuer)) SHENANDOAH ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Fil |
|
| August 9, 2023 |
Press Release issued by Lilly on August 9, 2023. EX-99.(a)(5)(C) Exhibit (a)(5)(C) For Release: Aug. 9, 2023 Refer to: Jordan Bishop; [email protected]; 317-473-5712 (Media) Joe Fletcher; [email protected]; 317-296-2884 (Investors) Lilly Completes Acquisition of DICE Therapeutics INDIANAPOLIS, Aug. 9, 2023 — Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ: |
|
| August 9, 2023 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) DICE THERAPEUTICS, INC. (Name of Subject Company (issuer)) DURNING ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Filing Pe |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 8, 2023 ELI LILLY AND COMPANY (Exact Name of Registrant as Specified in its Charter) Indiana 001-06351 35-0470950 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 8, 2023 |
Aug. 8, 2023 For Release: Immediately Refer to: Jordan Bishop; [email protected]; (317) 473-5712 (Media) Joe Fletcher; [email protected]; (317) 296-2884 (Investors) Lilly Reports Second-Quarter 2023 Financial Results, Highlights Accelerating Revenue Growth and Key Pipeline Advancements •Revenue in Q2 2023 increased 28% as a result of volume-driven growth from Mounjaro, Verzenio, Jardiance |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2023 COMMISSION FILE NUMBER 001-6351 ELI LILLY AND COMPANY (Exact name of Registrant as specified in its charter) Indiana 35-0470950 (State or other jurisdiction of (I.R.S. Employer incorpor |
|
| August 1, 2023 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) SIGILON THERAPEUTICS, INC. (Name of Subject Company (issuer)) SHENANDOAH ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Fil |
|
| July 25, 2023 |
Press Release issued by Lilly on July 25, 2023. EX-99.(a)(5)(B) Exhibit (a)(5)(B) For Release: July 25, 2023 @ 6:55 a.m. ET Refer to: Jordan Bishop; [email protected]; 317-473-5712 (Media) Joe Fletcher; [email protected]; 317-296-2884 (Investors) Lilly Announces Extension of Tender Offer to Acquire DICE INDIANAPOLIS, July 25, 2023 – Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to |
|
| July 25, 2023 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No.2) DICE THERAPEUTICS, INC. (Name of Subject Company (issuer)) DURNING ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Filing Per |
|
| July 18, 2023 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) SIGILON THERAPEUTICS, INC. (Name of Subject Company (issuer)) SHENANDOAH ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Fil |
|
| July 17, 2023 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No.1) DICE THERAPEUTICS, INC. (Name of Subject Company (issuer)) DURNING ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Filing Per |
|
| July 13, 2023 |
SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 SIGILON THERAPEUTICS, INC. (Name of Subject Company (issuer)) SHENANDOAH ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Filing Persons (identif |
|
| July 13, 2023 |
Summary Advertisement, as published in The Wall Street Journal on July 13, 2023. EX-99.(a)(1)(E) Exhibit (a)(1)(E) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). The Offer (as defined below) is being made only by the Offer to Purchase, dated July 13, 2023 (the “Offer to Purchase”) and the related Letter of Transmittal (the “Letter of Transmittal”), as each may be amended or supplemented from time to time, and |
|
| July 13, 2023 |
EX-99.(a)(1)(D) Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of SIGILON THERAPEUTICS, INC. at $14.92 per share, net in cash, without interest and less any applicable tax withholding, plus one non-tradable contingent value right (“CVR”) per share, which represents the contractual right to receive contingent payments of up to an aggregate of $111.64 per CVR, net to the |
|
| July 13, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Schedule TO SIGILON THERAPEUTICS, INC. |
|
| July 13, 2023 |
Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees. EX-99.(a)(1)(C) Exhibit (a)(1)(C) Offer to Purchase All Outstanding Shares of Common Stock of SIGILON THERAPEUTICS, INC. at $14.92 per share, net in cash, without interest and less any applicable tax withholding, plus one non-tradable contingent value right (“CVR”) per share, which represents the contractual right to receive contingent payments of up to $111.64 per CVR, net to the stockholder in c |
|
| July 13, 2023 |
Form of Letter of Transmittal (including Internal Revenue Service Form W-9). EX-99.(a)(1)(B) Exhibit (a)(1)(B) LETTER OF TRANSMITTAL to Tender Shares of Common Stock of SIGILON THERAPEUTICS, INC. at $14.92 per share, net in cash, without interest and less any applicable tax withholding, plus one non-tradable contingent value right (“CVR”) per share, which represents the contractual right to receive contingent payments of up to an aggregate of $111.64 per CVR, net to the st |
|
| July 13, 2023 |
EX-99.(d)(6) Exhibit (d)(6) MUTUAL CONFIDENTIALITY AGREEMENT THIS MUTUAL CONFIDENTIALITY AGREEMENT (the “Agreement”) is made on the date of acceptance (the “Effective Date”), between Eli Lilly and Company, having its principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285, U.S.A. (“Lilly”); and Sigilon Therapeutics, Inc., having its principal place of business at 100 Bin |
|
| July 13, 2023 |
Offer to Purchase, dated July 13, 2023. EX-99.(a)(1)(A) Table of Contents Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of SIGILON THERAPEUTICS, INC. at $14.92 per share, net in cash, without interest and less any applicable tax withholding, plus, one non-tradable contingent value right (“CVR”) per share, which represents the contractual right to receive contingent payments in an aggregate amount of up to $1 |
|
| July 7, 2023 |
EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement is being jointly filed, and all amendments thereto will be jointly filed, by Eli Lilly and Company, as the main and designated filer, on behalf of each of the persons and entities named below that is name |
|
| July 7, 2023 |
SGTX / Sigilon Therapeutics Inc / ELI LILLY & Co - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Sigilon Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 82657L107 (CUSIP Number) Anat Hakim Executive Vice President, General Counsel and Secretary Eli Lilly and Company Lilly Corporate Center Indianapolis, |
|
| July 7, 2023 |
EX-2.2 Exhibit 2.2 TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of June 28, 2023, is entered into by and among Eli Lilly and Company, an Indiana corporation (“Parent”), Shenandoah Acquisition Corporation, a Delaware corporation and a direct wholly-owned subsidiary of Parent (“Purchaser”), and one or more stockholders of Sigilon Therapeutics, Inc., a D |
|
| June 30, 2023 |
EX-99.(d)(5) Exhibit (d)(5) FIRST AMENDMENT TO CONFIDENTIALITY AGREEMENT Eli Lilly And Company and DICE Therapeutics, Inc. entered into a Confidentiality Agreement effective April 21, 2022 (the “Agreement”). This amendment (“Amendment”) forms part of and is hereby incorporated by reference into the Agreement. By this Amendment, the parties agree to, and hereby: (a) extend the term of the Agreement |
|
| June 30, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Schedule TO DICE THERAPEUTICS, INC. |
|
| June 30, 2023 |
EX-99.(a)(1)(D) Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of DICE THERAPEUTICS, INC. at $48.00 per share, net in cash, without interest and less any applicable tax withholding Pursuant to the Offer to Purchase dated June 30, 2023 by DURNING ACQUISITION CORPORATION a wholly-owned subsidiary of ELI LILLY AND COMPANY THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE |
|
| June 30, 2023 |
Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees. EX-99.(a)(1)(C) Exhibit (a)(1)(C) Offer to Purchase All Outstanding Shares of Common Stock of DICE THERAPEUTICS, INC. at $48.00 per share, net in cash, without interest and less any applicable tax withholding Pursuant to the Offer to Purchase dated June 30, 2023 by DURNING ACQUISITION CORPORATION a wholly-owned subsidiary of ELI LILLY AND COMPANY THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE |
|
| June 30, 2023 |
Form of Letter of Transmittal (including Internal Revenue Service Form W-9). EX-99.(a)(1)(B) Exhibit (a)(1)(B) LETTER OF TRANSMITTAL to Tender Shares of Common Stock of DICE THERAPEUTICS, INC. at $48.00 per share, net in cash, without interest and less any applicable tax withholding Pursuant to the Offer to Purchase dated June 30, 2023 by DURNING ACQUISITION CORPORATION a wholly-owned subsidiary of ELI LILLY AND COMPANY THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MI |
|
| June 30, 2023 |
Offer to Purchase, dated June 30, 2023. EX-99.(a)(1)(A) Table of Contents Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of DICE THERAPEUTICS, INC. at $48.00 per share, net in cash, without interest and less any applicable tax withholding by DURNING ACQUISITION CORPORATION a wholly-owned subsidiary of ELI LILLY AND COMPANY THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE PAST 11:59 P.M., EASTERN TIME |
|
| June 30, 2023 |
SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 DICE THERAPEUTICS, INC. (Name of Subject Company (issuer)) DURNING ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Filing Persons (identifying s |
|
| June 30, 2023 |
EX-99.(d)(4) Exhibit (d)(4) Contract No.: ICMConfidentialityAgreement6334 CONFIDENTIALITY AGREEMENT THIS CONFIDENTIALITY AGREEMENT (the “Agreement”) is made on the last date signed below, (the “Effective Date”), between Eli Lilly And Company, having its principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285, United States (“Lilly”), and DiCE Therapeutics, Inc. having it |
|
| June 30, 2023 |
Summary Advertisement, as published in The Wall Street Journal on June 30, 2023. EX-99.(a)(1)(E) Exhibit (a)(1)(E) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). The Offer (as defined below) is being made only by the Offer to Purchase, dated June 30, 2023 (the “Offer to Purchase”) and the related Letter of Transmittal, as each may be amended or supplemented from time to time, and is being made to all holders |
|
| June 29, 2023 |
Exhibit 99.1 June 29, 2023 For Release: June 29, 2023 @ 6:45 a.m. ET Refer to: Jordan Bishop; [email protected]; 317-473-5712 (Media) Joe Fletcher; [email protected]; 317-296-2884 (Investors) Amy Bonanno; [email protected]; 914-450-0349 (Sigilon Media) Lilly to Acquire Sigilon Therapeutics INDIANAPOLIS and CAMBRIDGE, Mass., June 29, 2023 – Eli Lilly and Company (NYSE: LLY) and Sig |
|
| June 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 SIGILON THERAPEUTICS, INC. (Name of Subject Company (issuer)) SHENANDOAH ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Filing Persons (identifying sta |
|
| June 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K ý ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022. OR o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-06351 A.Full title of the plan and the addr |
|
| June 20, 2023 |
EX-99.1 Exhibit 99.1 June 20, 2023 For Release: June 20, 2023 @ 6:45 a.m. ET Refer to: Jordan Bishop; [email protected]; 317-473-5712 (Media) Joe Fletcher; [email protected]; 317-296-2884 (Investors) Dan Budwick; [email protected] (DICE Media and Investors) Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology INDIANAPOLIS and SOUTH SAN FRANCISCO, Calif., June 20, 2023 – El |
|
| June 20, 2023 |
SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 DICE THERAPEUTICS, INC. (Name of Subject Company (issuer)) DURNING ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Filing Persons (identifying s |
|
| May 5, 2023 |
Conflict Minerals Report of Eli Lilly and Company for the year ended December 31, 2022 Exhibit 1.01 Eli Lilly and Company Conflict Minerals Report For the Year Ended December 31, 2022 As required by Rule 13p-1 under the Securities Exchange Act of 1934 (the “Rule”), Eli Lilly and Company (the “Company”) has filed this Conflict Minerals Report (the “Report”). This Report covers Company products manufactured from January 1 through December 31, 2022 for which columbite-tantalite (coltan |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report ELI LILLY AND COMPANY (Exact name of registrant as specified in its charter) Indiana 001-06351 (State or other jurisdiction of incorporation) (Commission File Number) Lilly Corporate Center Indianapolis, Indiana (Address of principal executive offices) Jonathan Groff (317-450-5089) (Name a |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 1, 2023 ELI LILLY AND COMPANY (Exact Name of Registrant as Specified in its Charter) Indiana 001-06351 35-0470950 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2023 COMMISSION FILE NUMBER 001-6351 ELI LILLY AND COMPANY (Exact name of Registrant as specified in its charter) Indiana 35-0470950 (State or other jurisdiction of (I.R.S. Employer incorpo |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 27, 2023 ELI LILLY AND COMPANY (Exact Name of Registrant as Specified in its Charter) Indiana 001-06351 35-0470950 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| April 27, 2023 |
April 27, 2023 For Release: Immediately Refer to: Jordan Bishop; [email protected]; (317) 473-5712 (Media) Joe Fletcher; [email protected]; (317) 296-2884 (Investors) Lilly Reports First-Quarter 2023 Financial Results, Highlights Continued Core Business Growth and Pipeline Momentum •Revenue in Q1 2023 decreased 11% driven by a $1.47 billion decline in revenue from COVID-19 antibodies. Excl |
|
| April 21, 2023 |
Notice of Exempt Solicitation Name of Registrant: Eli Lilly and Company Name of Person Relying on Exemption: SEIU Benefit Plans Master Trust Address of Person Relying on Exemption: 1800 Massachusetts Avenue, NW, Washington, DC 20036 April 20, 2023 Dear Fellow Eli Lilly Shareholder, Though companies have a legitimate business interest in influencing laws and regulations, such activities carry numerous risks. |
|
| April 10, 2023 |
April 10, 2023 To Eli Lilly and Company Stockholders: CommonSpirit Health, along with co-filers including School Sisters of Notre Dame, Sisters of St. |
|
| April 4, 2023 |
Main Post Office, P.O. Box 751 www.asyousow.org Berkeley, CA 94704 BUILDING A SAFE, JUST, AND SUSTAINABLE WORLD SINCE 1992 Notice of Exempt Solicitation Pursuant to Rule 14a-103 Name of the Registrant: Eli Lilly and Co. (LLY) Name of persons relying on exemption: As You Sow Address of persons relying on exemption: Main Post Office, P.O. Box 751, Berkeley, CA 94704 Written materials are submitted p |
|
| March 24, 2023 |
PX14A6G 1 o324232px14a6g.htm NOTICE OF EXEMPT SOLICITATION NAME OF REGISTRANT: Eli Lilly and Company NAME OF PERSON RELYING ON EXEMPTION: Trinity Health ADDRESS OF PERSON RELYING ON EXEMPTION: Catherine Rowan Dear Fellow Eli Lilly Shareholder, Trinity Health and co-filers Adrian Dominican Sisters, Mercy Investment Services, Bon Secours Mercy Health, Sisters of Charity of St. Elizabeth, Sisters of |
|
| March 22, 2023 |
Eli Lilly and Company (LLY) Shareholder Alert Voluntary submission by John Chevedden, POB 2673, Redondo Beach, CA 90278 Eli Lilly shareholder since 2018 Vote for Both Simple Majority Vote Proposals 6 and 8 To emphasize support for Proposals 6 and 8 – Consider voting against Mr. |
|
| March 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| March 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| March 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 17, 2023 ELI LILLY AND COMPANY (Exact Name of Registrant as Specified in its Charter) Indiana 001-06351 35-0470950 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| February 24, 2023 |
424B2 Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No. 333-262943 Prospectus Supplement (To Prospectus dated February 24, 2022) $4,000,000,000 Eli Lilly and Company $750,000,000 5.000% Notes Due 2026 Interest payable on February 27 and August 27 $1,000,000,000 4.700% Notes Due 2033 Interest payable on February 27 and August 27 $1,250,000,000 4.875% Notes Due 2053 Interest payabl |
|
| February 24, 2023 |
EX-1.1 Exhibit 1.1 Underwriting Agreement February 23, 2023 J.P. Morgan Securities LLC Credit Suisse Securities (USA) LLC Goldman Sachs & Co. LLC Morgan Stanley & Co. LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Credit Suisse Securities (USA) LLC Eleven Madison Avenue New York, New York |
|
| February 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 23, 2023 ELI LILLY AND COMPANY (Exact Name of Registrant as Specified in its Charter) Indiana 001-06351 35-0470950 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 24, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables(1) 424(b)(2) (Form Type) Eli Lilly and Company (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Debt 5. |
|
| February 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| February 24, 2023 |
Form of Officers’ Certificate setting forth the terms and form of the Notes. EX-4.3 Exhibit 4.3 ELI LILLY AND COMPANY Officers’ Certificate Pursuant to Section 3.01 of the Indenture , 2023 The undersigned, Philip Johnson, Group Vice President, Treasurer and Head of Corporate Transactions of Eli Lilly and Company, an Indiana corporation (the “Company”), and Jonathan Groff, Senior Director – Corporate Securities and Assistant Secretary of the Company, pursuant to Section 3.0 |
|
| February 23, 2023 |
SUBJECT TO COMPLETION PRELIMINARY PROSPECTUS SUPPLEMENT, DATED FEBRUARY 23, 2023 424B2 Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No. 333-262943 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities is effective under the Securities Act of 1933, as amended. We are not using this preliminary prospectus supplement and the accompanying prospectus to offer to sell or |
|
| February 23, 2023 |
FWP Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement No. 333-262943 Dated February 23, 2023 Eli Lilly and Company $4,000,000,000 aggregate principal amount of Notes offered Pricing Term Sheet 5.000% Notes due 2026 (the “2026 Notes”) 4.700% Notes due 2033 (the “2033 Notes”) 4.875% Notes due 2053 (the “2053 Notes”) 4.950% Notes due 2063 (the “2063 Notes”) (collectively, the |
|
| February 22, 2023 |
Exhibit 21 — List of Subsidiaries & Affiliates The following are subsidiaries and affiliated corporations of the company at December 31, 2022. |
|
| February 22, 2023 |
Exhibit 10.2 Form of Performance Award under the 2002 Lilly Stock Plan Eli Lilly and Company Performance Award Agreement (for Executive Officers) This Performance Award has been granted on [•] (“Grant Date”) by Eli Lilly and Company, an Indiana corporation, with its principal offices in Indianapolis, Indiana (“Lilly” or the “Company”), to the Eligible Individual who has received this Performance A |
|
| February 22, 2023 |
EX-10.5 5 lly-20221231x10kexhibit105.htm EX-10.5 Exhibit 10.5 Form of Non-Compete Payment Agreement Eli Lilly and Company Lilly Corporate Center Indianapolis, Indiana 46285 U.S.A. +1.317.276.2000 www.lilly.com [•], [•] [Name] [Address] [Address] Re: Non-Compete Payment Agreement Dear [Name]: This sets forth the terms of the Non-Compete Payment Agreement (the “Agreement”) between [name] (“Executive |
|
| February 22, 2023 |
Form of Shareholder Value Award under the 2002 Lilly Stock Plan Exhibit 10.3 Form of Shareholder Value Award under the 2002 Lilly Stock Plan Eli Lilly and Company Shareholder Value Award Agreement (for Executive Officers) This Shareholder Value Award has been granted on [•] (“Grant Date”) by Eli Lilly and Company, an Indiana corporation, with its principal offices in Indianapolis, Indiana (“Lilly” or the “Company”), to the Eligible Individual who has received |
|
| February 22, 2023 |
United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-K Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2022 Commission file number 001-06351 ELI LILLY AND COMPANY (Exact name of Registrant as specified in its charter) Indiana 35-0470950 (State or other jurisdiction of (I.R.S. Employer incorporati |
|
| February 22, 2023 |
Form of Relative Value Award under the 2002 Lilly Stock Plan Exhibit 10.4 Form of Relative Value Award under the 2002 Lilly Stock Plan Eli Lilly and Company Relative Value Award Agreement (for Executive Officers) This Relative Value Award has been granted on [•] (“Grant Date”) by Eli Lilly and Company, an Indiana corporation, with its principal offices in Indianapolis, Indiana (“Lilly” or the “Company”), to the Eligible Individual who has received this Rela |
|
| February 10, 2023 |
LLY / Eli Lilly And Co / PNC FINANCIAL SERVICES GROUP, INC. - SC 13G/A Passive Investment SC 13G/A 1 d248716dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 3) Eli Lilly and Company (Name of Issuer) Common Stock (Title of Class of Securities) 532457108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| February 9, 2023 |
LLY / Eli Lilly And Co / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0802-elilillyco.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Eli Lilly & Co. Title of Class of Securities: Common Stock CUSIP Number: 532457108 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule |
|
| February 2, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 2, 2023 ELI LILLY AND COMPANY (Exact Name of Registrant as Specified in its Charter) Indiana 001-06351 35-0470950 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| February 2, 2023 |
Feb. 2, 2023 For Release: Immediately Refer to: Jordan Bishop; [email protected]; (317) 473-5712 (Media) Joe Fletcher; [email protected]; (317) 296-2884 (Investors) Lilly Reports Fourth-Quarter 2022 Financial Results, Core Business Growth and Pipeline Advancements Support Strong Long-Term Outlook •Revenue in Q4 2022 decreased 9%. Excluding COVID-19 antibodies, revenue in Q4 2022 increased |
|
| January 27, 2023 |
ACIU / AC Immune SA / ELI LILLY & Co - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No: 1)* AC Immune SA (Name of Issuer) Common Stock, par value CHF 0.02 per share (Title of Class of Securities) H00263105 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| January 27, 2023 |
DTIL / Precision BioSciences Inc / ELI LILLY & Co - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No: 1)* Precision BioSciences, Inc. (Name of Issuer) Common Stock, par value $0.000005 per share (Title of Class of Securities) 74019P108 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desi |
|
| January 25, 2023 |
LLY / Eli Lilly And Co / LILLY ENDOWMENT INC - NONE Passive Investment SC 13G/A 1 doc1.htm NONE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 38)* Eli Lilly and Company (Name of Issuer) Common Stock, Without Par Value (Title of Class of Securities) 532457-10-8 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| December 23, 2022 |
PRQR / ProQR Therapeutics N.V. / ELI LILLY & Co - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* ProQR Therapeutics N.V. (Name of Issuer) Ordinary Shares, nominal value 0.04 EUR per share (Title of Class of Securities) N71542109 (CUSIP Number) December 21, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des |
|
| December 13, 2022 |
Lilly Announces 2023 Financial Guidance, Plans to Launch up to Four New Medicines Dec. 13, 2022 For Release: Immediately Refer to: Jordan Bishop; [email protected]; (317) 473-5712 (Media) Joe Fletcher; [email protected]; (317) 296-2884 (Investors) Lilly Announces 2023 Financial Guidance, Plans to Launch up to Four New Medicines •Lilly expects to deliver strong financial and operational performance in 2023, highlighted by volume-driven revenue growth; potential launches |
|
| December 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 13, 2022 ELI LILLY AND COMPANY (Exact Name of Registrant as Specified in its Charter) Indiana 001-06351 35-0470950 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 1, 2022 |
Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases EX-2.6 Exhibit 2.6 Dec. 1, 2022 For Release: Dec. 1, 2022 @ 8:41 a.m. ET Refer to: Jordan Bishop; [email protected]; 317-473-5712 (Media) Joe Fletcher; [email protected]; 317-296-2884 (Investors) Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases INDIANAPOLIS, Dec. 1, 2022 — Eli Lilly and Company (NYSE: LLY) today announced the successful completio |
|
| December 1, 2022 |
AKUS / Akouos Inc / ELI LILLY & Co - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 1)* Under the Securities Exchange Act of 1934 Akouos, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 00973J101 (CUSIP Number) Anat Hakim Executive Vice President, General Counsel and Secretary Eli Lilly and Company Lilly Corporate Center India |
|
| November 30, 2022 |
EX-99.A5B Exhibit (a)(5)(B) Nov. 30, 2022 For Release: Nov. 30, 2022 @ 6:50 a.m. ET Refer to: Jordan Bishop; [email protected]; 317-473-5712 (Lilly Media) Joe Fletcher; [email protected]; 317-296-2884 (Lilly Investors) Lee-Ann Murphy; [email protected] (Akouos Media) Courtney Turiano; [email protected] (Akouos Investors) Lilly and Akouos Announce Expiration of Akouos Tender Off |
|
| November 30, 2022 |
SC TO-T/A 1 d424354dsctota.htm SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) AKOUOS, INC. (Name of Subject Company (issuer)) KEARNY ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) |
|
| November 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) AKOUOS, INC. (Name of Subject Company (issuer)) KEARNY ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Filing Persons (identifying sta |
